


THE CLAIMS

What is claimed is:

1. A composition for treating renal fibrosis, comprising a pharmaceutically effective amount of a compound in combination with a pharmaceutically acceptable carriers, said compound being a member of a group having the general formula:



wherein: $n=1-2$

R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;


R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; and

R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof.

2. The composition of claim 1, wherein said compound is halofuginone.


3. The composition of claim 1 wherein said pharmaceutically acceptable carrier enables administration of the composition orally or parenterally in form of powder, granules, suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.

4. A method for treating renal fibrosis in a subject, comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition comprising as an active ingredient a compound having the general formula:



wherein: $n=1-2$

- 5 R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;
- R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; and
- R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof.
- 10
5. The method of claim 4, wherein said compound is halofuginone.
6. The method of claim 4, wherein said pharmaceutical composition is suitable for administration orally or parenterally in the form of powder, granules,
- 15 suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.
7. The method of claim 4, wherein the renal fibrosis condition is primary or secondary.
- 20
8. The method of claim 7 wherein the secondary condition is caused by hypertension, diabetic complications, or autoimmune diseases.
9. A method for preventing renal fibrosis from progressing to end-stage renal
- 25 failure comprising administering to a subject in need thereof a therapeutically effective amount of compound in a pharmaceutically acceptable carrier, said compound being a member of a group having the general formula:



wherein: $n=1-2$

R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;


R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; and

R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and pharmaceutically acceptable salts thereof.

10. The method of claim 9, wherein said compound is halofuginone.

11. The method of claim 9, wherein said pharmaceutically acceptable carrier enables administration of the composition orally or parenterally in the form of powder, granules, suspensions or solutions in water or non aqueous media, sachets, capsules or tablets.

12. A method for preparing a pharmaceutical composition for treating renal fibrosis which comprises combining a compound being a member of the group having the general formula:



wherein: $n=1-2$

R_1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy;

R_2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; and
 R_3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl,
and pharmaceutically acceptable salts thereof, with a pharmaceutically acceptable
carrier to form the composition. for preparing a pharmaceutical composition for
treating renal fibrosis.

13. The method of claim 12, wherein the compound is halofuginone.

14. The method of claim 12, wherein said medicament is suitable for
administration orally or parenterally in the form of powder, granules,
suspensions or solutions in water or non aqueous media, sachets, capsules or
tablets.